ACS INDUSTRY SYMPOSIUM , RECENT ADVANCES IN DRUG DEVELOPMENT HYDERABAD, INDIA, Dr. REDDYS, Nov 11-12 2016

GROUP PICTURE

Inaugural ACS Industry Symposium, 11-12 November 2016 in Hyderabad, India

Recent Advances in Drug Development

ACS2016 ACS Symposium at Dr. Reddy's Hyderabad, India, Nov 11-12 2016

ACS INDUSTRY SYMPOSIUM , RECENT ADVANCES IN DRUG DEVELOPMENT
HYDERABAD, INDIA, http://acssymposium.org.in/ 

The American Chemical Society (ACS) hosted the inaugural ACS Industry Symposium at Dr. Reddy’s Laboratories in Hyderabad, India , The event featured lectures on Recent Advances in Drug Development by the world’s leading researchers and experts.

ACS MOMENTO

With Jasmine , ASQ CQE, CPGP
Quality by Design , PARINCIPAL SCIENTIST at Dr. Reddy's Laboratories, At ACS 2016 — at Dr. Reddys Laboratories , Leadership Academy, Bachupally, Hyderabad.

With my GLENMARK PHARMACETICALS colleagues, ASHOK KADAM AND DR PRASADA LINGAM RAO , ACS2016 ACS Symposium at Dr. Reddy's Hyderabad, India, Nov 11-12 2016 ........ACS INDUSTRY SYMPOSIUM , RECENT ADVANCES IN DRUG DEVELOPMENT
HYDERABAD, INDIA, http://acssymposium.org.in/— with Prasada Lingam, Ashok Kadam and Rakeshwar Bandichhor.

with Rakeshwar Bandichhor and Aishal Crasto.

PROF. Ramachary Dhevalapally, ACS2016 ACS Symposium at Dr. Reddy's Hyderabad, India, Nov 11-12 2016 ........ACS INDUSTRY SYMPOSIUM , RECENT ADVANCES IN DRUG DEVELOPMENT
HYDERABAD, INDIA, http://acssymposium.org.in/— with Swapnil Sonawane, Mansoor Khan, More Balasaheb M, Ramachary Dhevalapally, Srinivas Oruganti, Pramod Chaudhari, Aishal Crasto, Mohan Thakur and Anamik Shah at Dr. Reddys Laboratories , Leadership Academy, Bachupally, Hyderabad.

SUNITHA VYALA

ACS2016 ACS Symposium at Dr. Reddy's Hyderabad, India, Nov 11-12 2016 ........ACS INDUSTRY SYMPOSIUM , RECENT ADVANCES IN DRUG DEVELOPMENT

HYDERABAD, INDIA, http://acssymposium.org.in/The American Chemical Society (ACS) hosted the inaugural ACS Industry Symposium at Dr. Reddy’s Laboratories in Hyderabad, India , The event featured lectures on Recent Advances in Drug Development by the world’s leading researchers and experts. — with Anil Gupta, ANKIT GUPTA, ANPHAR and Srinivasa Reddy.

 ACS2016 ACS Symposium at Dr. Reddy's Hyderabad, India, Nov 11-12 2016 ........ACS INDUSTRY SYMPOSIUM , RECENT ADVANCES IN DRUG DEVELOPMENT
HYDERABAD, INDIA, http://acssymposium.org.in/The American Chemical Society (ACS) hosted the inaugural ACS Industry Symposium at Dr. Reddy’s Laboratories in Hyderabad, India , The event featured lectures on Recent Advances in Drug Development by the world’s leading researchers and experts. — with Arun S. Agnihotri and PROF MING-WEI-WANG.

ACS2016 ACS Symposium at Dr. Reddy's Hyderabad, India, Nov 11-12 2016 ........ACS INDUSTRY SYMPOSIUM , RECENT ADVANCES IN DRUG DEVELOPMENT
HYDERABAD, INDIA, http://acssymposium.org.in/The American Chemical Society (ACS) hosted the inaugural ACS Industry Symposium at Dr. Reddy’s Laboratories in Hyderabad, India , The event featured lectures on Recent Advances in Drug Development by the world’s leading researchers and experts. — with JACOB KONYSZ, ACS GLOBAL STRATEGY, Anil Gupta and ANKIT GUPTA, ANPHAR.

With Padma Shri on Prof. (Dr.) Ganapati Dadasaheb Yadav, VC of ICT, ACS2016 ACS Symposium at Dr. Reddy's Hyderabad, India, Nov 11-12 2016 ........ACS INDUSTRY SYMPOSIUM , RECENT ADVANCES IN DRUG DEVELOPMENT
HYDERABAD, INDIA, http://acssymposium.org.in/— with PROF G D YADAV , ICT and Ravi Raghavan.

with Swapnil Sonawane at Dr. Reddys Laboratories , Leadership Academy, Bachupally, Hyderabad.

PROF ANAMIK SHAH, 

with Aishal Crasto, Pramod Chaudhari, Pallavi Rao and DR PALLAVI RAO DR REDDYS.

//////////A PRESENTATION

The presentation will load below

A VIDEO

Pics of CHIRAL INDIA 2016, 5th International Conference & Exhibition Nov 8-9 2016, Holiday Inn, Mumbai, India

At Chiral India 2016, New horizons in Drug development, Harnessing the power of Chirality .Organised by chemical weekly at Holiday inn international, Mumbai, India, Nov 8-9, 2016, 5th International Conference & Exhibition

With DR CHRISTOPHER WELCH, MERCK, USA, At Chiral India 2016, New horizons in Drug development, Harnessing the power of Chirality .Organised by chemical weekly at Holiday inn international, Mumbai, India, Nov 8 2016 

With Dr Vilas Dahanukar, Chief scientist, process R &D, Dr Reddys Laboratories, At Chiral India 2016, New horizons in Drug development, Harnessing the power of Chirality .Organised by chemical weekly at Holiday inn international, Mumbai, India, Nov 8 2016

At Chiral India 2016, New horizons in Drug development, Harnessing the power of Chirality .Organised by chemical weekly at Holiday inn international, Mumbai, India, Nov 8 2016 — with SINICHI SUMIDA and TAKEHISHA ISHIMARU.

With Karishma Badani Process Engineer, Nilsan Nishitech, At Chiral India 2016, New horizons in Drug development, Harnessing the power of Chirality .Organised by chemical weekly at Holiday inn international, Mumbai, India, Nov 8 2016 — with Mohan Thakur and karishma badani.

Mohan my attendant

 With Dr R RAJAGOPAL, Chemical weekly, At Chiral India 2016, New horizons in Drug development, Harnessing the power of Chirality .Organised by chemical weekly at Holiday inn international, Mumbai, India, Nov 8 2016

With Dr Ravi Raghavan, chemical weekly, At Chiral India 2016, New horizons in Drug development, Harnessing the power of Chirality .Organised by chemical weekly at Holiday inn international, Mumbai, India, Nov 8 2016 — with Mohan Thakurand Ravi Raghavan.

With Dr TIVADAR FARKAS, At Chiral India 2016, New horizons in Drug development, Harnessing the power of Chirality .Organised by chemical weekly at Holiday inn international, Mumbai, India, Nov 8 2016

 With Dr Laxmikant patkar, USV, At Chiral India 2016, New horizons in Drug development, Harnessing the power of Chirality .Organised by chemical weekly at Holiday inn international, Mumbai, India, Nov 8 2016 — with LAXMIKANT PATKAR USV.

 Full USV team @ Chiral India 2016, 5th International Conference and Exhibition.

With ICTIANS, At Chiral India 2016, New horizons in Drug development, Harnessing the power of Chirality .Organised by chemical weekly at Holiday inn international, Mumbai, India, Nov 8 2016 — with Rupesh U Shelke, Shreerang Joshi, Sandip Sabaleand Mohan Thakur.

India's only conference focusing on new chiral technologies for pharmaceutical fine chemicals. The event is a unique platform to learn about recent advances in chiral chemistry, technology and application. Chiral India series which began in 2012 has now grown into a major must-attend event for the Pharmaceutical industry. This platform is the most popular chiral technology platform bringing together the top experts from China, Canada, USA, Japan, India and other countries to present the latest developments in chiral drug developments and brainstorm with leading R&D personnel from Indian pharmaceutical industry. The fifth edition of Chiral India to be held on 8-9 November 2016, at Holiday Inn (Mumbai), follows the success of previous four annual editions (2012, 2013, 2014 and 2015) and is now an event awaited by R&D professionals across the industry.

International panel of Chiral experts will address on key Themes Asymmetric hydrogenations: New directions Chiral switches: Development of single enantiomer drugs Chiral tool kit in new drug development Organo molecular catalysts Enzymatic processes for new chiral drug synthesis Chiral chemistry in natural product synthesis Chiral catalysis: An overview of recent advances Chiral drugs: New regulatory directions Chiral separation technologies Flow reactions for chiral drug development

R  Rajagopal +9198211 28341 rraj@chemicalweekly.com kiran@chemicalweekly.com

Dr. R. Rajagopal	B-602, Godrej Coliseum	Tel: +91 22 24044477
Editorial Advisor	K.J. Somaiya Hospital Road	Fax: +91 22 24044450
Chemical Weekly	Sion (East) Mumbai 400 022	www.chemicalweekly.com

DOWNLOAD BROCHURE..... Please use http://www.chiralindia.com/Brochure.pdf link to download the Brochure. Our website URL is www.chiralindia.com  

Oganised By

   

  SCROLL USING MOUSE TO VIEW 5 PAGES




 ////////CHIRAL INDIA 2016, 5th International Conference, Exhibition,  Nov 8-9,  2016, Holiday Inn, Mumbai, India

Dhileep Krishnamurthy

Vice President & Head Global R&D API

links

https://in.linkedin.com/in/dhileep-krishnamurthy-b575b36

https://www.researchgate.net/profile/Dhileep_Krishnamurthy

Summary

Pharmaceutical API Process R&D (NCE and Generics) Executive with broad international experience

Specialties:- API R&D Strategy development and implementation
- People and Scientific leadership (multicultural and multinational)
- Discovery and Development of competitively advantaged routes for NCE, Generics and LCM APIs
- Implementation of R&D turnarounds
- Demonstrated cost savings over 5 million US$ for many NCE and Generics API using R&D initiatives


Over 20 years of scientific and R&D leadership experience in academic, multinational big pharma, CRO, CMO and generic pharmaceutical companies in synthetic organic chemistry, API process R&D and providing CMC support for filing IND, NDA, and DMF. Key experience in R&D strengthening using total synthesis, competitively advantaged route scouting, asymmetric catalysis, chemo catalysis, technology transfer of APIs, and building customer vendor relationship. Demonstrated leadership experience in managing QbD by DoE, bio-catalysis, analytical R&D, PAT, high throughput polymorph and catalysis screening using automation, and crystal engineering.

Motivational leadership style with a record of building highly motivated technical teams for innovation and productivity.

Experience

Vice President & Global Head - API R&D

Piramal Enterprises

February 2013 – Present (3 years 10 months)Mumbai Area, India

Leading the R&D organization (4 in India, 1 UK and 1 Canadian site) in API business (CRAMS and Generics)
• Providing guidance to global API R&D as a strategic partner for competitive advantage for API business
• Facilitating the development of break-through in new and competitively advantaged routes using modern synthesis/analytics and supporting technologies like bio-catalysis and chemo-catalysis

Developed R&D Vision and Strategy
• Crafted the long term vision for the R&D in API business and implementing along-with the business head and other stakeholders
• Developed and implemented the R&D strategy for growth as per the crafted vision

Providing technical support to BD, SM and Supply Chain and Regulatory
• Supporting BD and SM in Sales by attending the BD and SM discussions with client
• Provide technical inputs to proposal development especially for high value deals

People-development and recruitment
• Created a motivated and engaged team
• Coaching the R&D leads in each API sites, while working alongside the site heads
• Guiding the capability development in API R&D teams

(Open)1 honor or award

Vice President and Head (API, Route Scouting and New Technologies)

SAI Life Sciences Ltd

January 2012 – January 2013 (1 year 1 month)Hyderabad Area, India

Led the R&D organization in route scouting and technologies in API business (CRAMS and Generics)

Vice president & Head of Chemistry

Dr. Reddy's Laboratories

May 2011 – January 2012 (9 months)Hyderabad

• Provided scientific leadership support to management council of Dr. Reddy's from product selection to execution of projects in a timely and cost effective manner.
• Provided scientific leadership support to development of economical, novel and robust API processes for global generics and API markets.
• Provided leadership support to a team that is responsible for identifying and developing the novel polymorphic form for API.
• Provided technical leadership support to tech transfer and validation batches and ensure successful execution of commercial batches at manufacturing facility.
• Executed cost and quality improvement solutions to commercial API processes.
• Provided leadership support for managing and mentoring about 100 scientists working together to deliver several DMFs per year. Successfully solved many scientific challenges with other cross functional teams consist of scientists and project managers in formulations, analytical, regulatory, QA, QC, IPM and Engineering in a matrix environment.
• Demonstrated proof of concept has been demonstrated for obtaining Japan quality material with no extra cost by application of fundamental understanding of science and technology.
• Demonstrated proof of concept has been demonstrated for synthesis of many complex APIs using economical, green and novel route.
• Guided the team to identify and develop several novel polymorphs for many APIs.

Director - Process Research - Chemical Development, US

Boehringer Ingelheim Incorporation (USA)

December 2002 – April 2011 (8 years 5 months)CT, USA

Associate Research Fellow

Sunovion Pharmaceuticals Inc.

1999 – 2002 (3 years)Greater Boston Area, USA

Research Investigator

Bristol-Myers Squibb

1997 – 1999 (2 years)NJ, USA

Honors & Awards

Fellow of Royal Society of Chemistry

Royal Society of Chemistry- UK

January 2014

Achieving Fellow status in the chemical profession denotes to the wider community a high level of accomplishment as a professional chemist.

Gold Medal

Indian Chemical Society

August 1986

Topper at Aptitude test in Chemistry with in Greater Bombay

American Institute of Chemist Award

American Institute of Chemist

April 1995

Outstanding Ph.D Dissertation of the year

Henry Eyring Research Fellowship

Department of Chemistry, university of Utah

1989

Education

university of Utah, Salt Lake City, Utah (USA)

Doctor of Philosophy (Ph.D.), Synthetic Organic Chemistry

1989 – 1995

(Open)2 honors and awards

Indian Institute of Technology, Bombay

Master's Degree, Organic Chemistry

1986 – 1988

University of Mumbai

Bachelor's Degree, Chemistry

1983 – 1986

Vice President – Chemistry, Dr. Reddy’s Laboratories, INDIA

Dhileep holds a Ph.D. in Organic Chemistry from the University of Utah, US in 1995 and a Master's degree from Indian Institute of Technology Bombay. His Ph.D degree was focused on total synthesis of anti-tumor antibiotic natural product rhizoxin D and

the break through discovery of BITIP catalyzed asymmetric carbon-carbon bond forming reactions.

After a short Post-doctoral stint with Professor Gary Keck, he joined the process research group in Bristol-Myers Squib (BMS). At BMS he was instrumental in discovering the commercial route for anti-viral NCE "Entecavir". In 1999, he moved to Sepracor Inc., where his group contributed to number of fast track Improved Chemical Entities (ICE) projects. In late 2002, he joined Boehringer-Ingelheim (BI), where he was most recently served as Director for Process Research at R&D head quarter in USA. At BI, he held Management and Scientific responsibility of Process Chemistry group, Chemical Catalysis/Automation, Radio Synthesis group and API Crystallization group. His R&D responsibilities include design and synthesis of NCE based cGMP API's from multi gram to > 100 Kg for pre-clinical, clinical and formulation development. His research interest includes Discovery and Development of patent free, economical, green synthesis of API using traditional and modern approaches.

He has more than 60 Publications, Patents and Book Chapters. He has delivered many invited lectures in academic institutions and international professional conferences. Most recently, he served in the judging panel for the US Presidential Green Chemistry challenge award.

At present, Dr. Dhileep Krishnamurthy holds Vice President – Chemistry position and he is heading the chemistry function at IPDO, Dr. Reddy’s Laboratories, Hyderabad.

Dr. Dhileep Krishnamurthy's Abstract for IGCW 2011

Efficient Synthesis of Empagliflozin, an Inhibitor of SGLT-2, Utilizing an AlCl3-Promoted Silane Reduction of a β-Glycopyranoside

Xiao-jun Wang*, Li Zhang, Denis Byrne, Larry Nummy, Dirk Weber, Dhileep Krishnamurthy, Nathan Yee, andChris H. Senanayake

Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877, United States

Org. Lett., 2014, 16 (16), pp 4090–4093

DOI: 10.1021/ol501755h

Publication Date (Web): July 25, 2014

Copyright © 2014 American Chemical Society

*E-mail: xiao-jun.wang@boehringer-ingelheim.com.

Abstract

An efficient production synthesis of the SGLT-2 inhibitor Empagliflozin (5) from acid 1 is described. The key tactical stage involves I/Mg exchange of aryl iodide 2 followed by addition to glucono lactone 3 in THF. Subsequent in situ treatment of the resulting lactol with HCl in MeOH produces β-anomeric methyl glycopyranoside 4 which is, without isolation, directly reduced with Et3SiH mediated by AlCl3 as a Lewis acid in CH2Cl2/MeCN to afford 5 in 50% overall yield. The process was implemented for production on a metric ton scale for commercial launch.

Asymmetric Synthesis of LFA-1 Inhibitor BIRT2584 on Metric Ton Scale

Xiao-Jun Wang, Rogelio P. Frutos, Li Zhang, Xiufeng Sun, Yibo Xu, Thomas Wirth, Thomas Nicola, Lawrence J. Nummy, Dhileep Krishnamurthy, Carl A. Busacca, Nathan Yee, and Chris H. Senanayake

Org. Process Res. Dev., 2011, 15 (5), pp 1185–1191

Publication Date (Web): August 3, 2011 (Article)

DOI: 10.1021/op200175t

The synthesis of LFA-1 inhibitor BIRT2584 on metric-ton scale was accomplished by means of a safe and robust process. Highlights of the process include the asymmetric synthesis of the key advanced intermediate by implementation of Seebach’s self-...

Facile Entry to an Efficient and Practical Enantioselective Synthesis of a Polycyclic Cholesteryl Ester Transfer Protein Inhibitor

Zhengxu S. Han, Yibo Xu, Daniel R. Fandrick, Sonia Rodriguez, Zhibin Li, Bo Qu, Nina C. Gonnella, Sanjit Sanyal, Jonathan T. Reeves, Shengli Ma, Nelu Grinberg, Nizar Haddad, Dhileep Krishnamurthy, Jinhua J. Song, Nathan K. Yee, Waldemar Pfrengle, Markus Ostermeier, Jürgen Schnaubelt, Zeno Leuter, Sonja Steigmiller, Jürgen Däubler, Emanuel Stehle, Lukas Neumann, Thomas Trieselmann, Patrick Tielmann, Annette Buba, Rainer Hamm, Gunter Koch, Svenja Renner, Juan R. Dehli, Florian Schmelcher, Christian Stange, Jürgen Mack, Rainer Soyka, and Chris H. Senanayake

Org. Lett., 2014, 16 (16), pp 4142–4145

Publication Date (Web): August 1, 2014 (Letter)

DOI: 10.1021/ol501833g

An efficient enantioselective synthesis of the chiral polycyclic cholesteryl ester transfer protein (CETP) inhibitor 1 has been developed. The synthesis was rendered practical for large scale via the development of a modified Hantzsch-type reaction to ...

Wenjun Tang*, Bo Qu, Andrew G. Capacci, Sonia Rodriguez, Xudong Wei, Nizar Haddad, Bikashandarkoil Narayanan, Shengli Ma, Nelu Grinberg, Nathan K. Yee, Dhileep Krishnamurthy and Chris H. Senanayake

Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut 06877

Org. Lett., 2010, 12 (1), pp 176–179

DOI: 10.1021/ol9025815

Publication Date (Web): December 1, 2009

Copyright © 2009 American Chemical Society

wenjun.tang@boerhinger-ingelheim.com

Abstract

A series of novel, efficient, air-stable, and tunable chiral bisdihydrobenzooxaphosphole ligands (BIBOPs) were developed for rhodium-catalyzed hydrogenations of various functionalized olefins such as α-arylenamides, α-(acylamino)acrylic acid derivatives, β-(acylamino)acrylates, and dimethyl itaconate with excellent enantioselectivities (up to 99% ee) and reactivities (up to 2000 TON).

////////////////////